6DBM

Tyk2 with compound 23


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.368 Å
  • R-Value Free: 0.264 
  • R-Value Work: 0.201 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841).

Fensome, A.Ambler, C.M.Arnold, E.Banker, M.E.Brown, M.F.Chrencik, J.Clark, J.D.Dowty, M.E.Efremov, I.V.Flick, A.Gerstenberger, B.S.Gopalsamy, A.Hayward, M.M.Hegen, M.Hollingshead, B.D.Jussif, J.Knafels, J.D.Limburg, D.C.Lin, D.Lin, T.H.Pierce, B.S.Saiah, E.Sharma, R.Symanowicz, P.T.Telliez, J.B.Trujillo, J.I.Vajdos, F.F.Vincent, F.Wan, Z.K.Xing, L.Yang, X.Yang, X.Zhang, L.

(2018) J. Med. Chem. 61: 8597-8612

  • DOI: 10.1021/acs.jmedchem.8b00917
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Cytokine signaling is an important characteristic of autoimmune diseases. Many pro-inflammatory cytokines signal through the Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) pathway. JAK1 is important for the γ-common chain ...

    Cytokine signaling is an important characteristic of autoimmune diseases. Many pro-inflammatory cytokines signal through the Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) pathway. JAK1 is important for the γ-common chain cytokines, interleukin (IL)-6, and type-I interferon (IFN) family, while TYK2 in addition to type-I IFN signaling also plays a role in IL-23 and IL-12 signaling. Intervention with monoclonal antibodies (mAbs) or JAK1 inhibitors has demonstrated efficacy in Phase III psoriasis, psoriatic arthritis, inflammatory bowel disease, and rheumatoid arthritis studies, leading to multiple drug approvals. We hypothesized that a dual JAK1/TYK2 inhibitor will provide additional efficacy, while managing risk by optimizing selectivity against JAK2 driven hematopoietic changes. Our program began with a conformationally constrained piperazinyl-pyrimidine Type 1 ATP site inhibitor, subsequent work led to the discovery of PF-06700841 (compound 23), which is in Phase II clinical development (NCT02969018, NCT02958865, NCT03395184, and NCT02974868).


    Organizational Affiliation

    Medicine Design, Pfizer Inc., Eastern Point Road , Groton , Connecticut 06340 , United States.,Medicine Design, Pfizer Inc., 1 Portland Street , Cambridge , Massachusetts 02139 , United States.,Inflammation and Immunology, Pfizer Inc., 1 Portland Street , Cambridge , Massachusetts 02139 , United States.,Drug Safety Research and Development, Pfizer Inc., 1 Portland Street , Cambridge , Massachusetts 02139 , United States.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Non-receptor tyrosine-protein kinase TYK2
A
318Homo sapiensMutation(s): 5 
Gene Names: TYK2
EC: 2.7.10.2
Find proteins for P29597 (Homo sapiens)
Go to Gene View: TYK2
Go to UniProtKB:  P29597
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
G4J
Query on G4J

Download SDF File 
Download CCD File 
A
[(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone
C18 H21 F2 N7 O
BUWBRTXGQRBBHG-MJBXVCDLSA-N
 Ligand Interaction
Modified Residues  1 Unique
IDChainsTypeFormula2D DiagramParent
PTR
Query on PTR
A
L-PEPTIDE LINKINGC9 H12 N O6 PTYR
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
G4JIC50: 23 nM BINDINGMOAD
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.368 Å
  • R-Value Free: 0.264 
  • R-Value Work: 0.201 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 36.238α = 90.00
b = 73.317β = 90.00
c = 101.224γ = 90.00
Software Package:
Software NamePurpose
SCALAdata scaling
PDB_EXTRACTdata extraction
PHENIXrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2018-05-03 
  • Released Date: 2018-08-29 
  • Deposition Author(s): Vajdos, F.F.

Revision History 

  • Version 1.0: 2018-08-29
    Type: Initial release
  • Version 1.1: 2018-11-07
    Type: Data collection, Database references